GlassScriptPhysician profile
Peter A Bercz
NPI 1275725178
$14,178.96
in general payments reported to CMS, 2019-2025
46 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,419 · 2020: $582 · 2021: $4,801 · 2022: $2,045 · 2023: $1,173 · 2024: $1,317 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,054 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,054.02 |
| Education | $278.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,773.70 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,373.18 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Jazz Pharmaceuticals INC. | $844.04 | 2019-2024 | |
| Glaxosmithkline, LLC. | $817.41 | 2019-2025 | Nucala, Trelegy Ellipta |
| Veran Medical Technologies, INC. | $786.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $680.22 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $679.45 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $603.58 | 2019-2025 | Opsumit |
| Electromed, INC. | $549.62 | 2019-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $305.81 | 2019-2025 | Dupixent |
| Genzyme Corporation | $286.67 | 2021-2025 | |
| Inspire Medical Systems, INC. | $237.97 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $183.66 | 2023-2025 | Sunosi |
| Allergan, INC. | $173.90 | 2019-2020 | |
| Mylan Specialty L.P. | $170.82 | 2023-2024 | Yupelri |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $165.24 | 2022-2025 | Tezspire, Tavneos |
| Genentech USA, INC. | $148.88 | 2019-2025 | Xolair |
| Edwards Lifesciences Corporation | $134.26 | 2023 | Hemosphere |
| Merck Sharp & Dohme LLC | $126.17 | 2019-2025 | Winrevair |
| United Therapeutics Corporation | $125.03 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Avadel Cns Pharmaceuticals, LLC | $121.38 | 2025 | Lumryz |
| Philips North America LLC | $118.63 | 2019-2024 | (Ak6) Vest Therapy |
| Sunovion Pharmaceuticals INC. | $102.32 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.06 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $58.64 | 2022-2023 | Acthar |
| Viatris Specialty LLC | $57.31 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $48.03 | 2019-2022 | |
| Harmony Biosciences LLC | $47.50 | 2020-2024 | |
| Csl Behring | $39.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $38.48 | 2019-2021 | |
| Verona Pharma, INC. | $36.21 | 2025 | Ohtuvayre |
| Liquidia Technologies, INC. | $28.50 | 2025 | Yutrepia |
| Vapotherm INC | $27.47 | 2022 | |
| Gilead Sciences, INC. | $26.35 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $24.82 | 2022 | |
| Resmed Corp | $16.69 | 2025 | |
| Baxter Healthcare | $16.27 | 2023 | Hillrom - Life 2000 Ventilation System |
| Vifor Pharma, INC. | $14.67 | 2025 | Zemaira |
| Abbvie INC. | $13.79 | 2022 | |
| Cook Medical LLC | $13.29 | 2019 | |
| Inogen, INC. | $8.95 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bercz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.